Details
Debiopharm is a Swiss biopharmaceutical company focused on the development and manufacturing of innovative therapies, particularly in oncology and infectious diseases. Headquartered in Switzerland, it operates as both a drug developer and a contract manufacturing organisation for active pharmaceutical ingredients (APIs).
The company’s model is based on acquiring or in-licensing promising drug candidates, advancing them through clinical development, and partnering with larger pharmaceutical companies for global commercialisation. This allows Debiopharm to focus on research and development while leveraging partners for large-scale market distribution.
Its core therapeutic areas include cancer treatments, bacterial infections, and other serious diseases with high unmet medical need. The company is also involved in precision medicine approaches and innovative drug delivery systems aimed at improving treatment outcomes and patient safety.
Debiopharm operates with a strong emphasis on scientific research, clinical development, and pharmaceutical innovation, contributing to the global healthcare ecosystem through both proprietary development and strategic partnerships.